Agilent Technologies (A) 44th Annual J.P. Morgan Healthcare Conference summary

Strategic priorities and market positioning

• Focused on large, high-growth markets with secular drivers, including pharma, biotech, diagnostics, and applied markets, targeting $83B markets with 5-7% long-term core growth.

• Emphasis on customer-centricity, innovation, and leveraging the Ignite operating system for transformation and efficiency.

• Two-thirds of revenue now comes from recurring sources like consumables, services, and software, enhancing resilience; revenue mix for these segments grew 700bps over five years.

• Balanced global footprint, serving over 285,000 labs in 110 countries, with strong digital channel growth and 40% of orders now digital.

• Leading positions in chromatography, mass spectrometry, and spectroscopy, with customer retention rates above 90%.

Growth drivers and innovation

• Accelerating replacement cycles in LC and GC instruments, with significant productivity improvements and extended growth runway.

• Specialty CDMO growth driven by complex molecule outsourcing, strong GLP-1 and siRNA demand, and new siRNA API capacity coming in 2027 to double NASD revenue potential.

• Expansion in applied markets, especially PFAS testing, semiconductors, and battery testing.

• Digital and AI investments to enhance lab productivity and customer engagement, with AI focus ramping up in 2026.

• New product launches, such as the Altero Ultra Inert Column, Pro iQ Plus, and Infinity III LC, driving portfolio growth and differentiation.

Financial outlook and capital allocation

• FY26 guidance projects net revenue of $7.3B–$7.4B, core revenue growth of 4–6%, and EPS of $5.86–$6.00, underpinned by high single-digit pharma growth.

• Operating margin expansion of 50-100 basis points expected, with Ignite driving pricing and efficiency gains; FY25 operating margin was 25.7% (non-GAAP).

• China revenue expected to remain flat in FY26, with long-term optimism tied to innovation and regulatory trends.

• Specialty CDMO expected to grow at mid-teens rate in 2026, with strong order momentum in GLP-1 and siRNA.

• Disciplined M&A approach focused on strategic fit, recurring revenue, and integration capability, with no size limitations.